OncoMatch/Clinical Trials/NCT05838521
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
Is NCT05838521 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Sacituzumab govitecan for cervical cancer.
Treatment: Sacituzumab govitecan — This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Cervical Cancer
Biomarker criteria
Required: TACSTD2 any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage I, II, III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: chemotherapy — recurrent or persistent cervical cancer
have progressed following at least one prior chemotherapy treatment regimen
Cannot have received: topoisomerase I inhibitor
Have previously received topoisomerase I inhibitors
Cannot have received: irinotecan (irinotecan)
Exception: history of anaphylactic reaction or ≥ Grade 3 toxicity
history of an anaphylactic reaction to irinotecan or ≥ Grade 3 toxicity to prior irinotecan
Lab requirements
Blood counts
WBC ≥ 3,000/ul, Platelets ≥ 75,000/ul, Granulocytes ≥ 1500/ul
Kidney function
creatinine ≤ 2.0 mg/dL
Liver function
bilirubin ≤ 1.5 institutional upper limit of normal, AST and ALT ≤ 2.5 × IULN or ≤ 5 × IULN if known liver metastases
adequate bone marrow function: WBC ≥ 3,000/ul, Platelets ≥ 75,000/ul, Granulocytes ≥ 1500/ul. adequate renal function: creatinine ≤ 2.0 mg/dL. adequate hepatic function: bilirubin ≤ 1.5 institutional upper limit of normal, AST and ALT ≤ 2.5 × IULN or ≤ 5 × IULN if known liver metastases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Smilow Cancer Hospital at Yale New Haven · New Haven, Connecticut
- Cleveland Clinic · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05838521 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior topoisomerase I inhibitor, irinotecan disqualifies patients from enrollment.
Does this trial require TACSTD2?
Yes, TACSTD2 any tested is a required biomarker for enrollment.
What disease stage is eligible?
Stage I or II or III or IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages